Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy

被引:20
|
作者
Sun, Xiaoke [1 ]
Liu, Zhe [2 ]
Yang, Zhen [1 ]
Xiao, Lin [1 ]
Wang, Feng [1 ]
He, Yang [1 ]
Su, Pengxiao [1 ]
Wang, Junhu [1 ]
Jing, Baoli [1 ]
机构
[1] Xian Hong Hui Hosp, Dept Surg, Xian 710054, Peoples R China
[2] State Grid Corp China, Xian Elect Power Ctr Hosp, Dept Urol, Xian 710032, Peoples R China
来源
DIAGNOSTIC PATHOLOGY | 2013年 / 8卷
关键词
Prostate cancer; MicroRNA-126; Clinical pathology; Prognosis; DOWN-REGULATION; MIR-126; ANGIOGENESIS; CELLS;
D O I
10.1186/1746-1596-8-208
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Objective: Numerous studies have suggested that microRNA-126 (miR-126) is involved in development of various cancer types as well as in malignant proliferation and invasion. However, its role in human prostate cancer (PCa) is still unclear. The aim of this study was to investigate miR-126 expression in PCa and its prognostic value for PCa patients undergoing radical prostatectomy. Methods: A series of 128 cases with PCa were evaluated for the expression levels of miR-126 by quantitative reverse-transcription PCR (qRT-PCR). Kaplan-Meier analysis and Cox proportional hazards regression models were used to investigate the correlation between miR-126 expression and prognosis of PCa patients. Results: Compared with non-cancerous prostate tissues, the expression level of miR-126 was significantly decreased in PCa tissues (PCa vs. non-cancerous prostate: 1.05 +/- 0.63 vs. 2.92 +/- 0.98, P < 0.001). Additionally, the loss of miR-126 expression was dramatically associated with aggressive clinical pathological features, including advanced pathological stage (P = 0.001), positive lymph node metastasis (P = 0.006), high preoperative PSA (P = 0.003) and positive angiolymphatic invasion (P = 0.001). Moreover, Kaplan-Meier survival analysis showed that PCa patients with low miR-126 expression have shorter biochemical recurrence (BCR)-free survival than those with high miR-126 expression. Furthermore, multivariate analysis indicated that miR-126 expression was an independent prognostic factor for BCR-free survival after radical prostatectomy. Conclusion: These findings suggest for the first time that the loss of miR-126 expression may play a positive role in the malignant progression of PCa. More importantly, the downregulation of miR-126 may serve as an independent predictor of BCR-free survival in patients with PCa. Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1740080792113255.
引用
收藏
页数:6
相关论文
共 50 条
  • [11] Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer
    Malte Rieken
    Luis A. Kluth
    Evanguelos Xylinas
    Harun Fajkovic
    Andreas Becker
    Pierre I. Karakiewicz
    Michael Herman
    Yair Lotan
    Christian Seitz
    Paul Schramek
    Mesut Remzi
    Wolfgang Loidl
    Karl Pummer
    Richard K. Lee
    Talia Faison
    Douglas S. Scherr
    Alexandra Kautzky-Willer
    Alexander Bachmann
    Ashutosh Tewari
    Shahrokh F. Shariat
    World Journal of Urology, 2014, 32 : 999 - 1005
  • [12] Clinicopathological features of patients with biochemical recurrence after radical prostatectomy without progressive rise in serum prostate-specific antigen
    Miyake, Hideaki
    Hara, Isao
    Kurahashi, Toshifumi
    Muramaki, Mototsugu
    Yamanaka, Kazuki
    Inoue, Taka-aki
    Fujisawa, Masato
    UROLOGIA INTERNATIONALIS, 2006, 77 (03) : 200 - 204
  • [13] Risk-Adjusted Hazard Rates of Biochemical Recurrence for Prostate Cancer Patients after Radical Prostatectomy
    Walz, Jochen
    Chun, Felix K. H.
    Klein, Eric A.
    Reuther, Alwyn
    Graefen, Markus
    Huland, Hartwig
    Karakiewicz, Pierre I.
    EUROPEAN UROLOGY, 2009, 55 (02) : 412 - 421
  • [14] TWIST overexpression predicts biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy
    Raatikainen, Sami
    Aaltomaa, Sirpa
    Palvimo, Jorma J.
    Karja, Vesa
    Soini, Ylermi
    SCANDINAVIAN JOURNAL OF UROLOGY, 2015, 49 (01) : 51 - 57
  • [15] A qualitative transcriptional signature for predicting the biochemical recurrence risk of prostate cancer patients after radical prostatectomy
    Li, Xiang
    Huang, Haiyan
    Zhang, Jiahui
    Jiang, Fengle
    Guo, Yating
    Shi, Yidan
    Guo, Zheng
    Ao, Lu
    PROSTATE, 2020, 80 (05) : 376 - 387
  • [16] Decreased expression of microRNA-126 is associated with poor prognosis in patients with cervical cancer
    Yang, Yao
    Song, Kun-ling
    Chang, Hong
    Chen, Long
    DIAGNOSTIC PATHOLOGY, 2014, 9 : 220
  • [17] Expression of urokinase-type plasminogen activator system in prostate cancer: Correlation with clinicopathological outcomes in patients undergoing radical prostatectomy
    Kumano, Masafumi
    Miyake, Hideaki
    Muramaki, Mototsugu
    Furukawa, Junya
    Takenaka, Atsushi
    Fujisawa, Masato
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2009, 27 (02) : 180 - 186
  • [18] Overweight and obesity as risk factors for biochemical recurrence of prostate cancer after radical prostatectomy
    Sung Jin Kim
    Min Uk Park
    Han Kyu Chae
    Wook Nam
    So Won Kim
    Hoon Yu
    Han Gwun Kim
    Gil Hyun Kang
    Jong Yeon Park
    International Journal of Clinical Oncology, 2022, 27 : 403 - 410
  • [19] Overweight and obesity as risk factors for biochemical recurrence of prostate cancer after radical prostatectomy
    Kim, Sung Jin
    Park, Min Uk
    Chae, Han Kyu
    Nam, Wook
    Kim, So Won
    Yu, Hoon
    Kim, Han Gwun
    Kang, Gil Hyun
    Park, Jong Yeon
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (02) : 403 - 410
  • [20] The association between the interval from biopsy to radical prostatectomy and biochemical recurrence in patients with intermediate- and high-risk prostate cancer
    Siech, Carolin
    Wenzel, Mike
    Knoblich, Georgina
    Garcia, Cristina Cano
    Humke, Clara
    Preisser, Felix
    Traumann, Miriam
    Kluth, Luis A.
    Chun, Felix K. H.
    Mandel, Philipp
    FRONTIERS IN ONCOLOGY, 2025, 14